bioRxiv · 10.1101/2022.07.22.501017
Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment
Abstract
The hallmark amyloid-{beta} and tau deposition of Alzheimers disease (AD) represents only a fraction of its diverse pathophysiology. Molecular subtyping using large-scale -omic strategies can help resolve this biological heterogeneity. Using quantitative mass spectrometry, we measured ~8,000 proteins across >600 dorsolateral prefrontal cortex tissues from Religious Orders Study and Rush Memory and Aging Project participants with clinical diagnoses of no cognitive impairment, mild cognitive impairment (MCI), and AD dementia. Unbiased classification of MCI and AD cases based on individual proteomic profiles resolved three classes with expression differences across numerous cell types and biological ontologies. Two classes displayed molecular signatures atypical of those previously observed in AD neurodegeneration, such as elevated synaptic and decreased inflammatory markers. In one class, these atypical proteomic features were associated with clinical and pathological hallmarks of cognitive resilience. These results promise to better define disease heterogeneity within AD and meaningfully impact its diagnostic and therapeutic precision.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Higginbotham, L. A., Carter, E. K., Dammer, E. B., Haque, R. U., Johnson, E. C. B., Duong, D., Yin, L., De Jager, P. L., Bennett, D. A., Lah, J. J., Levey, A. I., Seyfried, N. T.. 2022-07-25. Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment. https://doi.org/10.1101/2022.07.22.501017
Cite the original work for its findings. Save a collection to share your selection of sources.